Literature DB >> 7643920

Characterization of non-adrenergic [3H]clonidine binding sites in rat stomach: high affinity of imidazolines, guanidines and sigma ligands.

G J Molderings1, K Donecker, M Göthert.   

Abstract

We have identified and characterized non-adrenergic [3H]clonidine binding sites in rat stomach. The binding of [3H]clonidine was rapid, reversible, partly specific (as defined by cirazoline 0.1 nmol/l), saturable and of high affinity. The specific binding of [3H]clonidine to rat stomach membranes was concentration-dependently inhibited by various imidazolines and guanidines including the sigma site ligand 1,2-di-(2-tolyl)guanidine (DTG), by the butyrophenone derivative (+)-3-PPP[(R)-3-(3-hydroxyphenyl)-N-propylpiperidine]; the latter two compounds are also known to exhibit affinity for sigma sites. In contrast, rauwolscine, histamine, ranitidine and the non-hydrolysable GTP-analogue Gpp(NH)p (5' guanylylimidodiphosphate) did not, or with negligible affinity, inhibit [3H]clonidine binding. In most cases, the competition curves were best fitted to a two-site model. The rank order of affinity for the high affinity site (in a few cases for a single detectable site) was as follows: cirazoline > idazoxan > or = DTG > (+)-3-PPP > chlonidine > guanabenz > haloperidol. This rank order is not compatible with the pharmacological properties of either I1- or I2-imidazoline binding sites. However, the ability of haloperidol, (+)-3-PPP and DTG to displace [3H]clonidine (the latter two with high affinity) suggests that the [3H] clonidine binding sites in rat stomach may be related to sigma-like sites.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7643920     DOI: 10.1007/bf00171049

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  19 in total

Review 1.  Sigma receptors: biology and function.

Authors:  J M Walker; W D Bowen; F O Walker; R R Matsumoto; B De Costa; K C Rice
Journal:  Pharmacol Rev       Date:  1990-12       Impact factor: 25.468

2.  Pharmacological characterization of the imidazoline receptor which mediates inhibition of noradrenaline release in the rabbit pulmonary artery.

Authors:  G J Molderings; F Hentrich; M Göthert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-12       Impact factor: 3.000

3.  Effects of histamine H2 receptor antagonists on acid secretion stimulated by imidazoline derivatives in isolated parietal cells.

Authors:  N Houi; Y Kamisaki; T Itoh
Journal:  Eur J Pharmacol       Date:  1987-11-24       Impact factor: 4.432

4.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

5.  Characterization of [3H]atipamezole as a radioligand for alpha 2-adrenoceptors.

Authors:  B Sjöholm; R Voutilainen; K Luomala; J M Savola; M Scheinin
Journal:  Eur J Pharmacol       Date:  1992-04-29       Impact factor: 4.432

6.  The imidazoline preferring receptor: binding studies in bovine, rat and human brainstem.

Authors:  G Bricca; M Dontenwill; A Molines; J Feldman; A Belcourt; P Bousquet
Journal:  Eur J Pharmacol       Date:  1989-03-14       Impact factor: 4.432

7.  Characterization of the alpha-2C adrenergic receptor subtype in the opossum kidney and in the OK cell line.

Authors:  H S Blaxall; T J Murphy; J C Baker; C Ray; D B Bylund
Journal:  J Pharmacol Exp Ther       Date:  1991-10       Impact factor: 4.030

8.  Characterization of specific (+)-[3H]N-allylnormetazocine and [3H]1,3-di(2-tolyl)guanidine binding sites in porcine gastric fundic mucosa.

Authors:  Y Harada; H Hara; T Sukamoto
Journal:  J Pharmacol Exp Ther       Date:  1994-06       Impact factor: 4.030

9.  Nonadrenergic imidazoline binding sites on human platelets.

Authors:  J E Piletz; K Sletten
Journal:  J Pharmacol Exp Ther       Date:  1993-12       Impact factor: 4.030

10.  Binding of [3H]clonidine to I1-imidazoline sites in bovine adrenal medullary membranes.

Authors:  G J Molderings; D Moura; K Fink; H Bönisch; M Göthert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-07       Impact factor: 3.000

View more
  3 in total

Review 1.  Biological significance of agmatine, an endogenous ligand at imidazoline binding sites.

Authors:  W Raasch; U Schäfer; J Chun; P Dominiak
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

2.  Inhibition of 5-HT3 receptor function by imidazolines in mouse neuroblastoma cells: potential involvement of sigma 2 binding sites.

Authors:  G J Molderings; K Schmidt; H Bönisch; M Göthert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996 Aug-Sep       Impact factor: 3.000

3.  Analysing the effect of I1 imidazoline receptor ligands on DSS-induced acute colitis in mice.

Authors:  Ágnes Fehér; Viktória E Tóth; Mahmoud Al-Khrasani; Mihály Balogh; Bernadette Lázár; Zsuzsanna Helyes; Klára Gyires; Zoltán S Zádori
Journal:  Inflammopharmacology       Date:  2016-11-21       Impact factor: 4.473

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.